Aptamers Industry Overview
The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030. Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.
Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.
Gather more insights about the market drivers, restrains and growth of the Aptamers Market
Detailed Segmentation:
Type Insights
Based on type, aptamers market is segmented into nucleic acid aptamers and peptide aptamers. Nucleic acid segment held the highest market share of 78.19% in 2022 and is expected to witness the highest growth during the forecast period. At present, many companies are investigating the mechanism of action of nucleic acid aptamers for the treatment of various disorders including age related muscular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted written agreement under Special Protocol Assessment (SPA) to IVERIC BIO (formerly known as Ophthotech Corporation) for the design of GATHER2 phase 3 clinical trial of Zimura for treatment of patients with GA secondary to AMD. This approval is expected to boost the segment growth.
Application Insights
Based on application, the aptamers market is segmented into diagnostics, therapeutics development, research and development, and others. The research & development segment held the highest market share of 31.38% in 2022. The growth of segment is attributed to rising demand for aptamers coupled with increasing research activities in this field have paved the way for aptamers demand in research and development field. There are various strategic initiatives undertaken by key players like collaborations, partnerships, & agreements for R&D of novel aptamers based diagnostic and therapeutic products. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research collaboration with an aim to support the discovery and development of aptamers based bispecific therapeutics. This collaboration evaluates the safety and efficacy of antigen specific SOMAmer reagents. Such an initiative is expected to boost the segment growth.
Regional Insights
North America region dominated the aptamers market with a share of 44.48% in 2022. The rising prevalence of chronic diseases, strong healthcare infrastructure, and growing interest of research laboratories in aptamer field are some of the major factors for the dominance of the region. Furthermore, in April 2022, Noxxon Pharma announced that it will present top line result data for its NOX-A12 GLORIA trial in brain cancer at the 2022 American Society of Clinical Oncology annual meeting.
Browse through Grand View Research's Biotechnology Industry Research Reports.
- The global DNA diagnostics market size was estimated at USD 10.61 billion in 2024 and is projected to grow at a CAGR of 8.7% from 2025 to 2030.
- The global CRISPR and Cas genes market size was estimated at USD 4.69 billion in 2024 and is projected to grow at a CAGR of 16.12% from 2025 to 2030.
Key Aptamers Companies:
- SomaLogic
- Aptamer Group
- Aptadel Therapeutics
- Base Pair Biotechnologies
- Noxxon Pharma
- Vivonics Inc.
- Aptagen, LLC
- TriLink Biotechnologies
- Altermune LLC
- AM Biotechnologies
Aptamers Market Segmentation
Grand View Research has segmented the global aptamers market on the basis of type, application, and region:
Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)
- Nucleic Acid Aptamer
- Peptide Aptamer
Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)
- Diagnostics
- Therapeutics
- Research & Development
- Others
Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.